Novartis is confident that Beovu continues to represent an important treatment option for patients with wet AMD, with an overall favorable benefit/risk profile.

Novartis is fully committed to keeping the retina community informed of the latest information pertaining to the safety of Beovu.

We would like to sincerely thank healthcare providers who have shared reports. You are encouraged to continue to report any observed or suspected adverse events according to local country requirements. You can also make a report to Novartis at

We will continue to provide regular updates on this website as new information becomes available.